Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD ... extension for Ozempic based on the results ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...

Why won’t my doctor prescribe Ozempic for weight loss? Between 10 and 20 per cent of patients with diabetes develop peripheral artery disease, said Dr. Leiter, who is also a professor of ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery disease (PAF ...